Background and aims: The impact of pain, fatigue, depression, spasticity and bladder dysfunction in patients with myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) and aquaporin‐4‐IgG‐seropositive neuromyelitis optica spectrum disorder (NMOSD‐AQP4+) is still unclear. This evidence concerns the gene AQP4 and neuromyelitis optica.